Avenacy, the injectable medicines company, will use the Milan show to showcase the successful launch of 13 FDA-approved injectable medications within its first year of operations. The company is on track to reach 25+ product launches in its first two years, aiming to address critical drug shortages in the U.S. market. With a growing portfolio, Avenacy will also discuss its unique packaging solutions and plans for further expansion.

Avenacy, a specialty pharmaceutical company focused on supplying critical medications, looks forward to celebrating its first year of growth and success since launching in October 2023. Backed by a robust global network of development and FDA-inspected contract manufacturing partners, Avenacy has already brought 13 injectable products to the U.S. market to address key gaps in the drug supply chain.

“We are incredibly proud of the achievements and progress we have made at Avenacy since launching nearly a year ago as a trusted partner and provider of critical injectable medicines for the U.S. healthcare system,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “We have acted swiftly and decisively to bring over a dozen medications to the U.S. market to help meet the needs of patients, strengthened our financial position with the addition of esteemed pharmaceutical investor and businessman, Dr. Patrick Soon-Shiong, and built out our infrastructure and leadership to support scaling up our business. As we look to usher in the next phase of growth for Avenacy, we will remain steadfast in our goal of enhancing patient care and enabling access to safe, high-quality essential medications.”

Through a rigorous and optimized selection process, Avenacy has launched thirteen products in the U.S. market, including:

• Melphalan Hydrochloride for Injection

• Bivalirudin for Injection

• Fosaprepitant for Injection

• Fulvestrant Injection

• Furosemide for Injection

• Desmopressin Acetate for Injection

• Eptifibatide for Injection

• Magnesium Sulfate in Water for Injection

• Isoproterenol Hydrochloride Injection, USP

• Tranexamic Acid Injection, USP

• Prochlorperazine Edisylate Injection, USP

• Palonosetron Hydrochloride Injection, USP

• Metoclopramide Injection, USP

The Company is well-positioned to continue expanding its differentiated portfolio to meet the needs of today’s dynamic drug supply chain while ensuring quality of care to patients.

All of Avenacy’s products feature unique packaging and labeling designed to assist healthcare providers with accurate medication selection, thereby supporting a reduction in administration errors and improper dosing. The Company also utilizes ready-to-use formulations of essential medications to help address dosing inaccuracies, enhance patient safety, and streamline efficiency – all with the ultimate goal of improving patient care.

Avenacy will be sharing its first year progress, differentiated business model, and diverse partner network at this year’s CPHI 2024 Conference, taking place in Milan from October 8-10. During this time, the Company will be hosting meetings with potential partners, customers, and investors, as it seeks to expand its global presence and portfolio of critical injectable medicines.

For more, please find the original story source here.